Streetwise Reports' Article Archives — Current Month (14)
Mining Company Uncovers High-Grade Tungsten in Portugal (10/02/2025)
Allied Critical Metals Inc. (ACM:CSE; ACMIF:OTCQB; 0VJ0:FSE) has reported new drill results from its Borralha Project in northern Portugal, including high-grade tungsten intercepts that extend mineralization beyond the current model. Read how these results position the project as a potential near-term supply source aligned with Western strategic priorities.
US Antimony Firm Wins Supply Contract from DOD (10/02/2025)
United States Antimony Corp. (UAMY:NYSEAmerican) will provide antimony ingots to replenish the dwindling national defense inventory, noted an Alliance Global Partners report.
Clean Tech Co.'s 'Forever Chemical' Solution Is a PFAS Breakthrough (10/02/2025)
Clean technology company BioLargo Inc. (BLGO:OTCQX) announced compelling new findings about its proprietary Aqueous Electrostatic Concentration (AEC) "forever chemicals" solution. Read to discover why one expert thinks the breakthrough is important to the company's future.
Copper Is Making Some Strong Moves (10/02/2025)
Ron Struthers of Struthers Resource Stock Report reviews the copper market and shares a couple companies he thinks should be on your radar.
British Columbia and Yukon Heat Up for Gold Exploration (10/01/2025)
Companies like K2 Gold (KTO:TSXV; KTGDF:OTCQB), White Gold Corp. (WGO:TSX.V; WHGOF:OTCQX; 29W:FRA), Cassiar Gold Corp. (GLDC:TSX.V; CGLCF:OTCQX; 756:FRA), and Thunderbird Minerals (BIRD:TSXV) are expanding exploration in BC and the Yukon. These juniors are targeting high-grade gold and copper in proven mineral belts like the Quesnel Terrane and Tombstone Gold Belt.
Anticipated Gold/Antimony Project Gets Conditional Notice to Proceed (10/01/2025)
Perpetua Resources Corp. (PPTA:TSX; PPTA:NASDAQ) receives a conditional Notice to Proceed from the U.S. Forest Service for the Stibnite Gold Project. One analyst says the company is benefitting from rising gold and antimony prices.
Gold Co. Raises Funds to Achieve Commercial Production (10/01/2025)
West Red Lake Gold Mines Ltd. (WRLG:TSX.V; WRLGF:OTCQB; FRA:UJO) aims to reach this state by Q1/26 at its flagship Madsen project and intends to use another portion of the financing proceeds to advance its Rowan project to a prefeasibility study, noted a Cantor Fitzgerald report.
PEA Shows It is Viable to Add Second Mine at Project (10/01/2025)
Silver X Mining Corp. (AGX:TSX.V; AGXPF:OTC) plans to advance the Plata Mining Unit at its Nueva Recuperada project to production in 2026, noted a Fundamental Research Corp. report.
Experts: 'Careful' Canadian Borrowers Make for Resilient Mortgages (10/01/2025)
While some experts are worried about rising delinquencies in U.S. mortgage payments, others say Canadians are much more "careful borrowers" and the fallout isn't expected to be as high north of the border.
Energy Co's. Partner for Power Solutions With Excellent Upside Potential (10/01/2025)
The rapid shift towards renewable energy is revolutionizing how utilities plan and manage the grid, according to a new blog post. Read why one expert says Eguana Technologies Inc. (EGT:TSX.V; EGTYF:OTC) is positioning itself as a crucial player in the market.
Biotech Secures FDA Alignment on Late-Stage Duchenne Therapy (10/01/2025)
Capricor Therapeutics Inc. (CAPR:NASDAQ) reached agreement with the FDA to include HOPE-3 trial data in its BLA for Deramiocel, its cell therapy for Duchenne muscular dystrophy. With topline results due in Q4, learn how the company is advancing one of the few late-stage programs in this high-need rare disease space.
Gold Surges 2.7% (10/01/2025)
Barry Dawes of Martin Place Securities shares his thoughts on the gold and silver market and takes a look at a few gold majors.
Golden Cross Strikes, Delivers Big (10/01/2025)
Bob Moriarty of 321gold.com explains why he likes Golden Cross Resources Ltd. (AUX:TSXV).
Biotech Battles FDA, Target Price Shows Potential 90% Gains (10/01/2025)
Capricor Therapeutics Inc. (CAPR:NASDAQ) has recently been involved in a "tug-of-war with the FDA." Read on to see why one Roth analyst still rates this stock as a Buy.
More Archives
2025Sep Aug Jul Jun May Apr Mar Feb Jan
2024Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
